Formed by a cadre of veterans from Baxter Healthcare’s renal division, Sorbent Therapeutics Inc. is developing polymer drugs that treat disease through the management of sodium and fluid volume in the body. Those two factors, along with potassium reduction or retention depending upon the condition, are keys to addressing a string of related illnesses including end-stage renal disease and congestive heart failure. Sorbent’s polymer drugs remove sodium from the gastrointestinal tract but are not absorbed into the rest of the bloodstream, thereby minimizing any number of potential toxicity, bioavailability and metabolism risks.
750 East Bunker Court
Suite 900
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.
The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
